Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

278
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
278
Epigenetic Regulation01:46

Epigenetic Regulation

33.8K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.8K
Master Transcription Regulators02:23

Master Transcription Regulators

7.8K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.8K
GTPases and their Regulation02:14

GTPases and their Regulation

9.8K
Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒  small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
9.8K
Regulated Protein Degradation02:58

Regulated Protein Degradation

8.9K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

38.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer.

Current oncology (Toronto, Ont.)·2025
Same author

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.

The oncologist·2025
Same author

Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.

Future oncology (London, England)·2025
Same author

Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.

Therapeutic advances in medical oncology·2025
Same author

A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative).

Future oncology (London, England)·2025

Related Experiment Video

Updated: Feb 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Demystifying biosimilars: development, regulation and clinical use.

Hope S Rugo1, Robert M Rifkin2, Paul Declerck3

  • 1Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA.

Future Oncology (London, England)
|December 1, 2018
PubMed
Summary
This summary is machine-generated.

Biosimilars offer safe, effective, and more affordable alternatives to biologics, increasing patient access to vital treatments. This overview addresses knowledge gaps to build confidence in biosimilar development and use.

Keywords:
biosimilardevelopmentextrapolationinterchangeabilitymythsregulatory approval

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

816
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
08:14

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research

Published on: March 22, 2024

2.0K

Related Experiment Videos

Last Updated: Feb 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

816
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
08:14

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research

Published on: March 22, 2024

2.0K

Area of Science:

  • Biopharmaceutical science
  • Clinical pharmacology
  • Regulatory science

Background:

  • Biologics are crucial for treating various diseases but face access challenges.
  • Biosimilars are highly similar to reference products, ensuring comparable safety, purity, and potency.
  • Increasing biosimilar approvals necessitate a better understanding of their development and application.

Purpose of the Study:

  • To address existing knowledge gaps concerning biosimilar development.
  • To enhance understanding and confidence in the clinical use of biosimilars.
  • To explore the potential of biosimilars in improving patient access and outcomes.

Main Methods:

  • Literature review of regulatory approvals and clinical data.
  • Analysis of comparative studies on safety, efficacy, and immunogenicity.
  • Synthesis of information on economic benefits and patient access.

Main Results:

  • Biosimilars demonstrate high similarity to reference products with no clinically meaningful differences.
  • Potential for reduced treatment costs, leading to improved patient access and broader clinical use.
  • Growing body of evidence supports the safety and efficacy of approved biosimilars.

Conclusions:

  • Biosimilars represent a significant advancement in making biologic therapies more accessible.
  • Addressing knowledge gaps is key to fostering trust and maximizing the benefits of biosimilars.
  • Further understanding will support the expanded and confident use of biosimilars in healthcare.